Cite
HARVARD Citation
Takahashi, M. et al. (n.d.). ACT-1 Multicenter investigator-initiated registration-directed Phase 2 study of E7090 in subjects with advanced or recurrent solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial. Neuro-oncology advances. p. vi9. [Online].